Leveraging a deep bench of expertise and foundational experience in DNA medicine development, we’re driving research that has the potential to transform treatment paradigms and improve patients’ lives.
Molecular Aspects of Medicine
December 2023
The Journal of Infectious Diseases
January 2022
Open Forum Infectious Diseases
December 2021
npj Vaccines
October 2021
Nature Communications
May 2020
| Title | Disease Target | Product |
|---|---|---|
| Immunogenicity of a DNA vaccine candidate for COVID-19 Nature Communications — May 2020 |
COVID-19 | INO-4800 |
| 571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster Open Forum Infectious Diseases — December 2021 |
COVID-19 | INO-4800 |
| SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial The Journal of Infectious Diseases — January 2022 |
COVID-19 | INO-4800 |
| INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants npj Vaccines — October 2021 |
COVID-19 | INO-4800 |
| Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models Human Vaccines & Immunotherapeutics — November 2023 |
COVID-19 | INO-4800 |
SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases
© Copyright 2024 INOVIO Pharmaceuticals. All rights reserved.
